Gilead Sciences, Inc. (GILD)
$
120.41
-2.80 (-2.33%)
Key metrics
Financial statements
Free cash flow per share
7.6589
Market cap
149.4 Billion
Price to sales ratio
5.1362
Debt to equity
0.1308
Current ratio
1.5316
Income quality
1.1920
Average inventory
3.1 Billion
ROE
0.4074
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Gilead Sciences, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines addressing unmet medical needs in the United States, Europe, and internationally. The company has achieved a significant net income of $480,000,000.00 showcasing its strong financial health. The diluted EPS is $0.38 accounting for potential share dilution, which is an important metric for investors. Furthermore, the net income ratio stands at 0.02 reflecting the company's profitability margin effectively. Gilead's EBITDA is $4,434,000,000.00 serving as a key indicator of its operational profitability. Additionally, the gross profit ratio of 0.78 reflects the efficiency of the company's production and sales operations. The product portfolio includes Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla for HIV/AIDS treatment, as well as Veklury for COVID-19. Gilead also offers therapies for liver diseases, hematology, oncology, and related cell therapies. The company's collaborations with notable partners such as Arcus Biosciences, Pionyr Immunotherapeutics, and Bristol-Myers Squibb exemplify its strategic approach to innovation. Incorporated in 1987, Gilead is headquartered in Foster City, California. The stock is reasonably priced at $114.09 appealing to a broad range of investors. With a large market capitalization of $149,390,237,949.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its category. Moreover, the stock has a high average trading volume of 7,318,341.00 indicating strong liquidity, which is an essential factor for investors seeking reliable investments. By fulfilling unmet medical needs and maintaining strong financial metrics, Gilead Sciences continues to be a vital entity in its field, dedicated to providing effective solutions for serious health conditions while upholding a commitment to improvement and advancement in biopharmaceutical science.
Is Gilead Sciences, Inc. (GILD) a good investment?
Investing in Gilead Sciences, Inc. (GILD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Gilead Sciences, Inc. (GILD)'s stock forecast?
Analysts predict Gilead Sciences, Inc. stock to fluctuate between $88.57 (low) and $128.70 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Gilead Sciences, Inc.'s market capitalization?
As of 2025-12-12, Gilead Sciences, Inc.'s market cap is $149,390,237,949, based on 1,240,679,623 outstanding shares.
How does Gilead Sciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Gilead Sciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Gilead Sciences, Inc. pay dividends?
Gilead Sciences, Inc. pays dividends. The current dividend yield is 2.62%, with a payout of $0.79 per share.
How can I buy Gilead Sciences, Inc. (GILD) stock?
To buy Gilead Sciences, Inc. (GILD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GILD. Place an order (Market, Limit, etc.).
What is the best time to invest in Gilead Sciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Gilead Sciences, Inc. stock ever split?
Gilead Sciences, Inc.'s last stock split was 2:1 on 2013-01-28.
How did Gilead Sciences, Inc. perform in the last earnings report?
Revenue: $28,754,000,000 | EPS: $0.38 | Growth: -91.63%.
Where can I find Gilead Sciences, Inc.'s investor relations reports?
Visit https://www.gilead.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Gilead Sciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Gilead Sciences, Inc. stock?
All-time high: $128.70 (2025-11-20) | All-time low: $57.17 (2022-06-14).
What are the key trends affecting Gilead Sciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Ameriprise Financial Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 397.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,748,403 shares of the biopharmaceutical company's stock after buying an additional 5,392,191 shares during
defenseworld.net
AQR Capital Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 32.5% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,470,838 shares of the biopharmaceutical company's stock after buying an additional 606,168 shares during
reuters.com
Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
defenseworld.net
Ariel Investments LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 14.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 368,861 shares of the biopharmaceutical company's stock after selling 61,563 shares during the period. Ariel Investments LLC's holdings in Gilead
businesswire.com
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer.
seekingalpha.com
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
seekingalpha.com
Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
defenseworld.net
Aspire Growth Partners LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,910 shares of the biopharmaceutical company's stock, valued at approximately $212,000. A number of other hedge funds and
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
See all news
